FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987161010> ?p ?o ?g. }

• W2987161010 endingPage "4323" @default.
• W2987161010 startingPage "4323" @default.
• W2987161010 abstract "Deregulation of long non-coding RNAs (lncRNAs) is emerging as a common feature of different human tumors and their investigation may uncover novel biomarkers and oncogenic mechanisms. Previous studies have suggested that the alteration of some lncRNAs may play an important role in the pathogenesis of multiple myeloma (MM); however, the complete expression landscape of lncRNAs has not been elucidated. In the present work we characterized the lncRNAs transcriptome of MM and determined the potential involvement of lncRNAs in the pathogenesis and clinical behavior of MM. To characterize the MM transcriptome, we performed paired-end strand-specific RNA sequencing (ssRNA-seq) in 38 purified plasma cell (PC) samples from MM patients and in 3 bone marrow PCs (BMPCs) of healthy donors, as well as in distinct normal B-cell populations (Naïve, Centroblasts, Centrocytes, Memory and Tonsilar PCs). We identified 40,511 novel lncRNAs that were expressed, accounting for more than half of MM transcriptome (56%). This group of novel lncRNAs together with previously annotated lncRNAs comprised most (82%) of the MM transcriptome. We studied the transcriptional heterogeneity in MM samples and observed that lncRNAs showed a much more heterogeneous expression than coding genes, suggesting that these elements could contribute to the biological heterogeneity of the disease. Moreover, to determine differentially expressed genes, each MM patient was compared to normal BMPCs, detecting 19,886 lncRNAs deregulated (10,351 overexpressed and 9,535 downregulated) in more than 50% of patients. We then analyzed the transcriptional dynamics of MM considering the different stages of B-cell differentiation and focused on a group of 989 lncRNAs that were upregulated specifically in plasma cells from MM in comparison with the rest of B-cell stages (MM-specific lncRNAs). Next, we aimed to determine whether upregulation of MM-specific lncRNAs in MM was under epigenetic control so we analyzed the distribution of six histone modifications with non-overlapping functions (H3K4me3, H3K4me1, H3K27ac, H3K36me3, H3K27me3, and H3K9me3) of within the lncRNAs of interest by ChIP-seq in MM cases as compared to normal B cell subtypes. We detected 89 lncRNAs with de novo epigenomic activation. These data suggest an epigenetic rewiring in MM where the loci of most MM-specific lncRNAs are in an inactive state in normal cells and become active in MM. We focused on a specific lncRNA, LINC-SMILO, de novo epigenetically active and expressed in MM cells to determine whether upregulation of this lncRNA could play a role in the pathogenesis of the disease. Knockdown of LINC-SMILO in 3 different MM cell lines (MM.1S, MM.1R and KMS-11) using two different shRNAs, resulted in reduced proliferation and induction of apoptosis of myeloma cells. Using low input RNA-seq (MARS-seq), we found that inhibition of LINC-SMILO was associated with activation of ERVs (Endogenous retroviruses) and increase in interferon (IFN) induced genes and activation of IFN pathways, essential for MM cells survival. Finally, we aimed to determine whether the use of specific lncRNAs could improve the current prognostic stratification of MM patients using the IA11 release of CoMMpass data. We analyzed the prognostic value of lncRNAs using COX regression analysis and Backward elimination of Stepwise regression analysis, obtaining that the overexpression of the lncRNA PDLIM1P4 together with 1q amplification and 17p deletion stratified MM patients in three different risk groups (Figure 1). In summary, our study shows that the lncRNA transcriptome is widely altered in MM and suggests that some of the identified lncRNAs have marked prognostic influence and can be used as potential therapeutic targets for MM. Disclosures Paiva: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, and Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau. San-Miguel:Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Roche, Sanofi, and Takeda: Consultancy, Honoraria. Melnick:KDAc Therapeutics: Membership on an entity's Board of Directors or advisory committees; Constellation Pharmaceuticals: Consultancy; Epizyme: Consultancy; Janssenn: Research Funding." @default.
• W2987161010 created "2019-11-22" @default.
• W2987161010 creator A5000870253 @default.
• W2987161010 creator A5003098018 @default.
• W2987161010 creator A5010754980 @default.
• W2987161010 creator A5016030888 @default.
• W2987161010 creator A5019770989 @default.
• W2987161010 creator A5020488389 @default.
• W2987161010 creator A5029344488 @default.
• W2987161010 creator A5034854461 @default.
• W2987161010 creator A5036313621 @default.
• W2987161010 creator A5036685066 @default.
• W2987161010 creator A5038509968 @default.
• W2987161010 creator A5040584996 @default.
• W2987161010 creator A5042102666 @default.
• W2987161010 creator A5042659494 @default.
• W2987161010 creator A5049487102 @default.
• W2987161010 creator A5050845654 @default.
• W2987161010 creator A5053016495 @default.
• W2987161010 creator A5053612749 @default.
• W2987161010 creator A5057189669 @default.
• W2987161010 creator A5060282288 @default.
• W2987161010 creator A5073318665 @default.
• W2987161010 creator A5076844152 @default.
• W2987161010 creator A5086593940 @default.
• W2987161010 creator A5089163384 @default.
• W2987161010 creator A5090074814 @default.
• W2987161010 creator A5091271737 @default.
• W2987161010 date "2019-11-13" @default.
• W2987161010 modified "2023-10-18" @default.
• W2987161010 title "Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma" @default.
• W2987161010 doi "https://doi.org/10.1182/blood-2019-123008" @default.
• W2987161010 hasPublicationYear "2019" @default.
• W2987161010 type Work @default.
• W2987161010 sameAs 2987161010 @default.
• W2987161010 citedByCount "1" @default.
• W2987161010 countsByYear W29871610102023 @default.
• W2987161010 crossrefType "journal-article" @default.
• W2987161010 hasAuthorship W2987161010A5000870253 @default.
• W2987161010 hasAuthorship W2987161010A5003098018 @default.
• W2987161010 hasAuthorship W2987161010A5010754980 @default.
• W2987161010 hasAuthorship W2987161010A5016030888 @default.
• W2987161010 hasAuthorship W2987161010A5019770989 @default.
• W2987161010 hasAuthorship W2987161010A5020488389 @default.
• W2987161010 hasAuthorship W2987161010A5029344488 @default.
• W2987161010 hasAuthorship W2987161010A5034854461 @default.
• W2987161010 hasAuthorship W2987161010A5036313621 @default.
• W2987161010 hasAuthorship W2987161010A5036685066 @default.
• W2987161010 hasAuthorship W2987161010A5038509968 @default.
• W2987161010 hasAuthorship W2987161010A5040584996 @default.
• W2987161010 hasAuthorship W2987161010A5042102666 @default.
• W2987161010 hasAuthorship W2987161010A5042659494 @default.
• W2987161010 hasAuthorship W2987161010A5049487102 @default.
• W2987161010 hasAuthorship W2987161010A5050845654 @default.
• W2987161010 hasAuthorship W2987161010A5053016495 @default.
• W2987161010 hasAuthorship W2987161010A5053612749 @default.
• W2987161010 hasAuthorship W2987161010A5057189669 @default.
• W2987161010 hasAuthorship W2987161010A5060282288 @default.
• W2987161010 hasAuthorship W2987161010A5073318665 @default.
• W2987161010 hasAuthorship W2987161010A5076844152 @default.
• W2987161010 hasAuthorship W2987161010A5086593940 @default.
• W2987161010 hasAuthorship W2987161010A5089163384 @default.
• W2987161010 hasAuthorship W2987161010A5090074814 @default.
• W2987161010 hasAuthorship W2987161010A5091271737 @default.
• W2987161010 hasConcept C104317684 @default.
• W2987161010 hasConcept C150194340 @default.
• W2987161010 hasConcept C162317418 @default.
• W2987161010 hasConcept C18431079 @default.
• W2987161010 hasConcept C186836561 @default.
• W2987161010 hasConcept C203014093 @default.
• W2987161010 hasConcept C2776364478 @default.
• W2987161010 hasConcept C502942594 @default.
• W2987161010 hasConcept C54355233 @default.
• W2987161010 hasConcept C62203573 @default.
• W2987161010 hasConcept C67705224 @default.
• W2987161010 hasConcept C70721500 @default.
• W2987161010 hasConcept C86803240 @default.
• W2987161010 hasConceptScore W2987161010C104317684 @default.
• W2987161010 hasConceptScore W2987161010C150194340 @default.
• W2987161010 hasConceptScore W2987161010C162317418 @default.
• W2987161010 hasConceptScore W2987161010C18431079 @default.
• W2987161010 hasConceptScore W2987161010C186836561 @default.
• W2987161010 hasConceptScore W2987161010C203014093 @default.
• W2987161010 hasConceptScore W2987161010C2776364478 @default.
• W2987161010 hasConceptScore W2987161010C502942594 @default.
• W2987161010 hasConceptScore W2987161010C54355233 @default.
• W2987161010 hasConceptScore W2987161010C62203573 @default.
• W2987161010 hasConceptScore W2987161010C67705224 @default.
• W2987161010 hasConceptScore W2987161010C70721500 @default.
• W2987161010 hasConceptScore W2987161010C86803240 @default.
• W2987161010 hasIssue "Supplement_1" @default.
• W2987161010 hasLocation W29871610101 @default.
• W2987161010 hasOpenAccess W2987161010 @default.
• W2987161010 hasPrimaryLocation W29871610101 @default.
• W2987161010 hasRelatedWork W1971124177 @default.
• W2987161010 hasRelatedWork W1985116998 @default.
• W2987161010 hasRelatedWork W1985562003 @default.
• W2987161010 hasRelatedWork W2052655934 @default.

• next